e delivery attributes
and only marginally different safety attributes when compared with
paclitaxel/carboplatin," said Jenna Avent, analyst at Decision Resources.
"However, the regimen of Avastin plus paclitaxel/carboplatin has better
efficacy when compared to the current gold standard,
paclitaxel/carboplatin, and oncologists rate efficacy as the most important
parameter in the treatment of advanced ovarian cancer."
About the Report
Ovarian Cancer (Advanced): Therapies Must Increase Survival over
Paclitaxel/Carboplatin to Successfully Enter this Generic Market is a
DecisionBase 2008 report from Decision Resources. DecisionBase 2008
combines market forecasts with clinical and commercial end points to assess
market share projections in 35 indications. These outputs are driven by
quantitative and qualitative primary research. DecisionBase 2008 provides
detailed market share, patient share, and price-per-day projections for
emerging drugs in development. The market share projections are based on
prescriber surveys that compare physicians' expectations of a potential
target product profile with an emerging product profile of the leading
drugs in development.
The report can be purchased by contacting Decision Resources. Members
of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets. Decision Resources is a Decision Resources, Inc.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Page: 1 2 3 Related biology technology :1
|SOURCE Decision Resources, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists2
. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer3
. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial4
. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial5
. Combination vaccine protects monkeys from ebola and Marburg viruses6
. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management7
. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy8
. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination9
. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure10
. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy11
. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment